My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

1.410 -0.090 (-6.00%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Inhibikase Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

December 19, 2023

From Inhibikase Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 13, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 12, 2023

Via Benzinga

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 11, 2023

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

December 04, 2023

Via Benzinga

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

December 04, 2023

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics: Q3 Earnings Insights ↗

November 14, 2023

Via Benzinga

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

November 14, 2023

Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET

From Inhibikase Therapeutics

Via GlobeNewswire

Earnings Preview For Inhibikase Therapeutics ↗

November 13, 2023

Via Benzinga

Earnings Preview: Inhibikase Therapeutics ↗

May 12, 2023

Via Benzinga

FDA Removes Regulatory Overhang From Inhibikase Therapeutics Parkinson/Atrophy Program ↗

March 08, 2023

Via Benzinga

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

November 07, 2023

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023

November 07, 2023

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

October 16, 2023

From Inhibikase Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 04, 2023

Via Benzinga

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

October 04, 2023

From Inhibikase Therapeutics

Via GlobeNewswire

Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗

September 20, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday.

Via Benzinga

Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 04, 2023

Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 19, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 25, 2023

Via Benzinga

Why Avalo Therapeutics Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗

August 18, 2023

Gainers

Via Benzinga

Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology ↗

May 24, 2023

IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology.

Via Talk Markets

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

April 18, 2023

We're starting off the day with a look at the biggest pre-market stock movers traders will want to keep an eye on Tuesday!

Via InvestorPlace

Shares Of Inhibikase Therapeutics Stock Decouples From NASDAQ Weakness; Jump 8% Including A/H Wednesday As Interest In Ikt-148009 Intensifies ($IKT)

March 16, 2023

Via AB Newswire

Earnings Scheduled For August 14, 2023 ↗

August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 ↗

April 18, 2023

Via Benzinga

Inhibikase Therapeutics Stock Turns Bullish After FDA Lifts Full Clinical Hold For Lead Candidate IkT-148009 ($IKT)

March 14, 2023

Via AB Newswire

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 14, 2023

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...

Via Benzinga

Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 26, 2023

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement for up to $3.2 million.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.